Wednesday, November 9, 2011

Pharmacopoly

Listen to this well articulated manipulations of Big Pharma & FDA in allowing dangerous life threatening toxic drugs passed as "safe", inventing new diseases to fit Big Pharma's monopoly on health care, government health officials and medical professionals in collusion.

Lawlessness, anarchy, against the constitution, the FDA and Big Pharma ignore court orders!!




Watch live streaming video from projectcamelotlive at livestream.com

Monday, April 18, 2011

Health Quest Forum

All welcome to join, in particular, those who suffered adverse reactions (ADRs) from all antibiotics, including fluoroquinolones, lariam/mefloquine and those who had vaccines shots shortly before/after taking the aforementioned, (and other medications).

http://health-quest.proboards.com/index.cgi

FB: http://www.facebook.com/home.php#!/profile.php?id=100002311715945

The forum is an attempt at bringing all under one banner.


http://health-quest.proboards.com/index.cgi

FB: http://www.facebook.com/home.php#!/profile.php?id=100002311715945

Health Quest focuses on prevention (as in recovery or preventing more damage), solution and options. Info and tips, and is a springboard for support and HOPE.

Although many of us suffered primary symptoms and recovered, others, suffered long term chronic illness resulting from damage caused by antibiotics (and lariam/mefloquine) known to reactivate certain infectious pathogens, damage to mitochondria cascading in chronic inflammation leading to diseases, such as cardiovascular, metabolic syndromes, myopathies and other dysfunctions at cellular level.

Friday, March 18, 2011




Why is the UK Government consistently refusing to release information concerning ME/CFS? Information held by the UK Government will be not be made public until 2076....

Friday, March 11, 2011

See few articles below about drug metabolism
and mitochondria.

Clearly, prevention is paramount, secondly, look at other options of dealing with health issues, and thirdly, be responsible for your own health issues. Read up on the pharmacological content of prescribed meds, validity, the science, effective?, side effects and adverse reactions. Read about what other patients themselves experienced, over a period of time. Most who suffer ill health do not make the association with off the counter meds and/or prescribed meds. It takes longer than a few weeks or months, sometimes years for inflammation to progress.

Nuclear Receptors and the Regulation of Drug-Metabolizing Enzymes and Drug Transporters: Implications for Interindividual Variability in Response to Drugs

1. Bradley L. Urquhart, PhD
2. Rommel G. Tirona, PhD
3. Richard B. Kim, MD

1.
From the Division of Clinical Pharmacology, Department of Medicine (Dr Urquhart, Dr Tirona, Dr Kim), and the Department of Physiology & Pharmacology (Dr Tirona), University of Western Ontario, London, Ontario, Canada.

1. Address for correspondence: Richard B. Kim, MD, Division of Clinical Pharmacology, London Health Sciences Centre—University Hospital, Room ALL-152, 339 Windermere Road, London, Ontario N6A 5A5, Canada; e-mail: richard.kim@lhsc.on.ca.

Abstract

Erratic or unpredictable response to drugs remains a challenge of modern drug therapy. An important determinant of such interindividual differences in drug response is variability in the expression of drug-metabolizing enzymes and/or transporters at sites of absorption and/or tissue distribution. Variable drug-metabolizing enzyme and transporter expression can result in unpredictable exposure and tissue distribution of drugs and may manifest as adverse effects or therapeutic failure. In the past decade, important new insights have been made relating to the regulatory mechanisms governing the expression of drug-metabolizing enzymes and transporters by ligand-activated nuclear receptors. Specifically, there is compelling evidence to demonstrate that PXR, CAR, FXR, LXR, VDR, HNF4α, and AhR form a battery of nuclear receptors that regulate the expression of many important drug-metabolizing enzyme and transporters. In this review, the authors focus on clinically important drug-metabolizing enzymes such as CYP3A4, CYP2B6, CYP2C9, CYP2C19, UGT1A1, SULT2A1, and glutathione S-transferases and their regulation by nuclear receptors. They also review the nuclear receptor-mediated regulation of drug transporters such as MDR1, MRP2, MRP4, BSEP, BCRP, NTCP, OATP1B3, and OATP1A2. Finally, they outline how the drug development process has been affected by the current understanding of the involvement of nuclear receptors in the regulation of drug disposition genes. http://tinyurl.com/5t5qzcd

I was curious about comparative study for ADRs between Fqs and other antibiotics. Those who are suffering from ADRs, (NOT allergic reactions), from other antibiotics, take note. So yes, many of us, have/had ADRs from non FQs pre/post floxing!! Figures seem to vary, one other study show cephalosporins to be between 19-40%...

Abstract and Introduction
Abstract

Extensive pharmacologic and clinical development of quinolone antimicrobial agents has resulted in improved antimicrobial activity, pharmacokinetic features, toxicity, and drug-drug interaction profiles. Nalidixic acid and other early quinolones had limited use due to poor pharmacokinetics, relatively narrow antimicrobial spectrum of activity, and frequent adverse effects. Beginning with the development of fluoroquinolones, such as norfloxacin and ciprofloxacin, in the 1980s, the agents assumed a greatly expanded clinical role because of their broad antimicrobial spectrum of action, improved pharmacokinetic properties, and more acceptable safety profile. Although the pharmacokinetics and efficacy of the drugs have improved significantly, a major area of continued emphasis is to further reduce the frequency and severity of adverse events and drug-drug interactions. Older agents such as ciprofloxacin and ofloxacin are still extensively prescribed, but the focus of this article is on the newer fluoroquinolones (levofloxacin and other drugs that have been approved or have been under investigation since approximately 1997). http://www.medscape.com/viewarticle/418295

For those who are still keen on taking antibiotics, read about the mitochondria cytoxicity, which means essentially, DNA damage. There are several articles posted on the forum about damage to mitochondria, worse offenders are: antibiotics (Fqs, macrolides, tetracyclines, clyndamicin, Rifamopin), anti-depressants and NSAIDs... This study is well designed and discusses glycation, cell death, lactic acidosis etc. http://aac.asm.org/cgi/reprint/AAC.00729-05v1.pdf

For those of us who are having problems with foods, vits & supps, and metabolozing drugs, read on...

It appears that minute dosage of anything is not being metabolized (for some of us), and reaches a level of toxicity. This can apply to some compounds in some type of foods. This partly explains the inability to metabolize, the aforementioned including environmental pollutants.

"Enzymes that metabolize xenobiotics have historically
been called drug-metabolizing enzymes, although they are
involved in the metabolism of many foreign chemicals to
which humans are exposed. Dietary differences among
species during the course of evolution could account for
the marked species variation in the complexity of the
drug-metabolizing enzymes.

Today, most xenobiotics to which humans are exposed
come from sources that include environmental pollution,
food additives, cosmetic products, agrochemicals, processed
foods, and drugs. In general, these are lipophilic
chemicals, that in the absence of metabolism would not be
efficiently eliminated, and thus would accumulate in the
body, resulting in toxicity. With very few exceptions, all
xenobiotics are subjected to one or multiple pathways that
constitute the phase 1 and phase 2 enzymatic systems. As
a general paradigm, metabolism serves to convert these
hydrophobic chemicals into derivatives that can easily be
eliminated through the urine or the bile."http://books.mcgraw-hill.com/medical/goodmanandgilman/pdfs/CHAPTER3.pdf

Sunday, February 20, 2011

Hyaluronic Acid eye drops may help with joints pains. It was reported that some experienced relief from this.

The article mentions Hyaluronic Acid in cream form for joints pains.

http://www.pingueculae.com/index.php/eye-drops/134-hyaluronic-eye-drops-supplements

In addition, since there is accumulation of uric acid in joints causing pains, it might be worth trying a diet low in purines:

http://www.ehow.com/facts_5004026_what-foods-have-uric-acid.htm
l
Those of who have active EBV, HHV-6 following your ADRs from antibiotics, see the article below. There is strong evidence that antibiotics can reactivate the mentioned infectious pathogens. Its likely it activates other infectious pathogens, since antibiotics are immune suppressants. It seems that antibiotics dysregulate the immune system. Many complained of lyme disease symptoms, subsequently found to carry active Borrellia Burg, which were previously dormant.

Adverse antibiotic-induced eruptions associated with epstein barr virus infection and showing Kikuchi-Fujimoto disease-like histology.
Carlson JA, Perlmutter A, Tobin E, Richardson D, Rohwedder A.

Division of Dermatology, Department of Pathology, Albany Medical College, Albany, New York 12208, USA. carlsoa@mail.amc.edu

The antibiotic-induced eruption of infectious mononucleosis is a well-known clinical phenomenon. Latent viral infection with herpesviridae (eg, human herpes virus 6 (HHV-6) and Epstein-Barr virus (EBV)) is suspected to play a role in the drug hypersensitivity syndrome. The cutaneous pathologic findings have not been reported in the former, and are infrequently reported in the latter entity. Herein, we describe the biopsy findings of a cefprozil-induced rash in infectious mononucleosis and a minocycline-associated drug hypersensitivity syndrome. Biopsy of these exanthematous eruptions revealed an acute vacuolar interface superficial and deep perivascular and interstitial lymphocytic dermatitis. CD8(+) lymphocytes predominated and were associated with non-neutrophilic nuclear (karyorrhectic) debris and numerous small CD68(+) and CD123(+) monocytes. These aforementioned features have been described in cutaneous lesions of Kikuchi-Fujimoto disease, an entity whose clinicopathologic findings overlap with both infectious mononucleosis and lupus erythematosus. Serologic evidence of active and chronic active EBV infection was found in both patients, respectively. No evidence of EBV or HHV6 was found in the cutaneous lesions. Plasmacytoid monocytes (CD68(+)/CD123(+) cells), which produce type I interferon, are believed to play a role in viral immunity by protecting other cells from viral infections and promoting survival of antigen-activated T cells. Their presence in these two putative examples of viral-drug immune dysregulation could be a clue to pathogenesis and represent a common cellular component of some adverse cutaneous drug eruptions.

http://www.ncbi.nlm.nih.gov/pubmed/16456....Pubmed_RVDocSum
I was curious about comparative study for ADRs between Fqs and other antibiotics. Those who are suffering from ADRs, (NOT allergic reactions), from other antibiotics, take note. So yes, many of us, have/had ADRs from non FQs post floxing!!

Aside the well known side effects of FQs, other antibiotics also cause damage to tendons, CNS symptoms and so forth.

"adverse effects for various fluoroquinolones was 3-40%. By comparison, these same studies reported adverse event rates of 2-49% for trimethoprim-sulfamethoxazole, 6-35% for penicillins, 12-39% for cephalosporins, 19-23% for doxycycline, and approximately 39% for erythromycin.[10,11]"


Abstract and Introduction
Abstract

Extensive pharmacologic and clinical development of quinolone antimicrobial agents has resulted in improved antimicrobial activity, pharmacokinetic features, toxicity, and drug-drug interaction profiles. Nalidixic acid and other early quinolones had limited use due to poor pharmacokinetics, relatively narrow antimicrobial spectrum of activity, and frequent adverse effects. Beginning with the development of fluoroquinolones, such as norfloxacin and ciprofloxacin, in the 1980s, the agents assumed a greatly expanded clinical role because of their broad antimicrobial spectrum of action, improved pharmacokinetic properties, and more acceptable safety profile. Although the pharmacokinetics and efficacy of the drugs have improved significantly, a major area of continued emphasis is to further reduce the frequency and severity of adverse events and drug-drug interactions. Older agents such as ciprofloxacin and ofloxacin are still extensively prescribed, but the focus of this article is on the newer fluoroquinolones (levofloxacin and other drugs that have been approved or have been under investigation since approximately 1997).
Introduction

Fluoroquinolones are considered to be safe and well tolerated,[1-4] although there are some notable exceptions, for example, temafloxacin, trova-floxacin, and, more recently, grepafloxacin.[5-9] This is especially true when fluoroquinolones are compared with other commonly prescribed antimicrobials.[3, 4] A review of safety results from numerous controlled clinical trials revealed that, overall, the agents are not significantly different from -- and in some cases were superior to -- nonquinolone comparators or placebo in occurrence of adverse events.[10, 11] Overall rates of adverse effects and rates of drug discontinuation from premarketing clinical studies of fluoro-quinolones are summarized in Table 1. [2-4,6,7,10-44]

Fluoroquinolones are generally highly comparable with other classes of antibiotics in terms of overall frequency and severity of adverse effects, although specific adverse effects vary among drug classes. In comparative clinical studies, the overall frequency of adverse effects for various fluoroquinolones was 3-40%. By comparison, these same studies reported adverse event rates of 2-49% for trimethoprim-sulfamethoxazole, 6-35% for penicillins, 12-39% for cephalosporins, 19-23% for doxycycline, and approximately 39% for erythromycin.[10,11]

True rates of adverse effects are often extremely difficult to determine. Comparative clinical studies may report two types of adverse events: treatment-emergent and drug-related. Treatment-emergent adverse effects are reported by study participants during the study. These are frequently quite subjective and are often not related to the study drug(s). Therefore, adverse event rates associated with administration of placebo are often as high as those associated with active agents. Treatment-emergent event rates also reflect adverse effects that are drug related. Although these rates are often much higher than the frequency of true drug-related adverse effects, they are reported because of difficulty determining causality. Drug-related adverse effect rates, when available, are usually much more useful with regard to agents of different classes as well as to those of the same class. Adverse effect rates of fluoroquinolones summarized in Table 1 include those that were reported to be possibly or probably drug related.

Most adverse events caused by fluoroquinolones are comparable, although overall frequency and manifestation of certain adverse effects differ among agents ( Table 2 ).[4,10] Each fluoroquinolone tends to produce a characteristic profile of adverse effects; differences often are explained by structural features and related relationships of the class.[45] The events are typically mild and usually resolve during continued treatment or with discontinuation of therapy, although early discontinuation for an event is unusual. Gastrointestinal effects (e.g., nausea, diarrhea) and central nervous system (CNS) effects (e.g., headache, dizziness) are most common. Toxic effects that are observed only in animal models or that have not been shown to be clinically relevant in humans include chondrotoxicity, reproductive and developmental toxicity, genotoxicity, and carcinogenicity.[2-4,10,11] Concerns regarding bone and joint toxicities in juvenile animal models thus far have precluded approval of fluoroquinolones for treatment of infections in children. However, more recent data indicate that the agents may be safe in this population, and this is being actively explored.
http://www.medscape.com/viewarticle/418295

Read more: http://noquinolones.proboards.com/index.cgi?board=theories&action=display&thread=1813#ixzz1EWiceWCj

Tuesday, February 1, 2011

Please send your ADRs stories to Public Citizen. You can choose anonymity or give as much info as you want.



If you or someone close to you has been harmed because of a medical error, please share your story.
Go to www.citizen.org/medical-error-stories

Tuesday, January 18, 2011

Its no wonder that so many suffer ill health or ADRs from prescription drugs....

60 Minutes Exposes the Maker of the #1 Most Fatal Drug of 2009

From Dr Mercola's site:

Drug company whistle-blower Cheryl Eckard talks about her experience trying to fix problems at GlaxoSmithKline. Her discoveries about the dangerous practices of the company made her a key figure in a federal lawsuit.

...... Due to various production line failures, powerful medications were also getting mixed up. Potent and potentially dangerous drugs were literally ending up in the wrong bottles! The antidepressant Paxil was mixed into bottles of Avandia, a diabetes drug. And Avandia was found in packages of the over-the-counter antacid Tagamet. All in all, Eckard identified nine different mix-ups of various drugs. http://tinyurl.com/4dj8nfe

Tuesday, January 11, 2011


See other posts on Triphala, an Ayurvedic compound used for gentle detoxing, over a long period of time. It contains anti-oxidants compounds from three Asian fruits. The mix is anti bacterial, anti-viral, purifies the blood and organs, as well as aids the digestive system and bowel movement if taken at night. It also has various other beneficial properties as well as protection against radiation.

The article below discusses the radioprotective effects of Triphala:


The evaluation of the radioprotective effect of Triphala (an ayurvedic rejuvenating drug) in the mice exposed to [gamma]-radiation.

Summary

The effect of 0, 5, 6.25, 10, 12.5, 20, 25, 40, 50 and 80 mg/kg b. wt. of aqueous extract of triphala (an Ayurvedic herbal medicine) administrered intraperitoneally was studied on the radiation-induced mortality in mice exposed to 10 Gy of [gamma]-radiation. Treatment of mice with different doses of triphala consecutively for five days before irradiation delayed the onset of mortality and reduced the symptoms of radiation sickness when compared with the non-drug treated irradiated controls. The highest protection against GI (gastrointestinal) death was observed for 12.5 mg/kg triphala, where a highest number of survivors were reported up to 10 days post-irradiation. While 10 mg/kg triphala i.p. provided the best protection as evidenced by the highest number of survivors after 30 days post-irradiation in this group when compared with the other doses of triphala. Toxicity study showed that triphala was non-toxic up to a dose of 240 mg/kg, where no drug-induced mortality was observed. The [LD.sub.50] dose i.p. o f triphala was found to be 280 mg/kg b. wt. Our study demonstrates the ability of triphala as a good radioprotective agent and the optimum protective dose of triphala was 1/28 of its [LD.sub.50] dose.

Key words: Triphala, radiation, mice, survival, acute toxicity, radioprotection ra·di·o·pro·tec·tion
n.
Protection against the harmful effects of radiation.


radi·o·pro·tec
..... Click the link for more information., Terminalia chebula Retz., Phyllanthus emblica Linn. or Emblica officinalis Gaertn. and Terminalia bellerica (Gaertn.) Roxb.

Cont/.. http://tinyurl.com/4fyyfee

Friday, January 7, 2011

Another wonder cancer drug bites the dust!! None of these have shown to be helpful.

A significant percentage of newly diagnosed patients are turning to safer modalities. Sadly, most die of side effects from toxic drugs and invasive tests rather than the primary cancer. Furthermore, many cancer patients develop new cancers caused by chemo, radiation and arsenal of unnecessary drugs.

Breaking News: Popular Cancer Drug Declared More Harmful Than Helpful

The FDA has said that the controversial drug Avastin should be phased out as a treatment for metastatic breast cancer. Recent studies show that its benefits are outweighed by dangerous side effects.

The announcement does not affect Avastin's status as a drug that can be prescribed for lung cancer, kidney cancer, colorectal cancer and brain cancer.

In 2008, the FDA granted Avastin accelerated approval for use to treat metastatic breast cancer. But studies have failed to show that patients getting Avastin lived longer than patients on standard chemotherapies.

According to CNN:
"Along with those disappointing findings, serious side effects became apparent in patients taking Avastin, including high blood pressure, internal bleeding, perforated internal organs, heart failure and heart attacks, and in some cases, even swelling of the brain."

Genentech, which makes Avastin, has a right to appeal the decision.

Folks, the best way of preventing breast cancer isn't a drug at all, and it's free! Sun exposure may be the single most effective means of reducing breast cancer, thanks to vitamin D, which forms in your body in reaction to sunlight. In a recent study, data collected over a decade from more than 67,000 women showed that women in sunny climes with high vitamin D levels were at a significantly reduced risk of breast cancer!

Sources:
CNN December 16, 2010
Cancer Epidemiology, Biomarkers and Prevention December 2, 2010


Popular Breast Cancer Drug Proven More Harmful than Helpful

Avastin, which costs about $8,000 a month and is one of the best-selling cancer drugs in the world, is now being phased out in the US due to lack of effectiveness and dangerous side effects.

As reported by CNN, the FDA has deemed the drug to be more harmful than beneficial based on recent studies, and recommends phasing it out as a treatment for metastatic breast cancer.

The drug will still maintain its status as an approved therapy for lung-, kidney-, colorectal- and brain cancer, however.
The European Medicines Agency is also altering its recommendation, but rather than withdrawing approval entirely, Avastin will now only be prescribed in combination with the drug Paclitaxel for the treatment of breast cancer in the EU.

List of some Fluoroquinolones Antibiotics

List of some fluoroquinolones antibiotics- for list of symptoms go to: www.fluoroquinolones.org
forum: www.favc.info


Generic & Brand Name of most common Fluoroquinolones

Brand Name: Trovan - Zithromax
Generic Name: Trovafloxacin and Azithromycin

Brand Name: Factive
Generic Name: Gemifloxacin Mesylate

Brand Name: Zagam
Generic Name: Sparfloxacin

Brand Name: Vigamox
Generic Name: Moxifloxacin

Brand Name: Vigamox
Generic Name: Moxifloxacin

Brand Name: Cinobac
Generic Name: Cinoxacin

Brand Name: Penetrex
Generic Name: Enoxacin

Brand Name: Tequin
Generic Name: Gatifloxacin (Removed from US Market - May 2006)

Brand Name: Levaquin
Generic Name: Levofloxacin

Brand Name: Floxin
Generic Name: Ofloxacin

Brand Name: Synercid
Generic Name: Quinupristin and Dalfopristin

Brand Name: Trovan - Zithromax

Brand Name: Zymar
Generic Name: Gatifloxacin Ophthalmic Solution

Brand Name: Avelox
Generic Name: Moxifloxacin HCL

Brand Name: Floxin Otic Singles

Brand Name: Ciprodex
Generic Name: Ciprofloxacin and Dexamethasone

Brand Name: Raxar
Generic Name: Grepafloxacin

Brand Name: Ocuflox
Generic Name: Ofloxacin Ophthalmic

Brand Name: Quixin
Generic Name: Levofloxacin

Brand Name: Cipro
Generic Name: Ciprofloxacin

Brand Name: Proquin XR
Generic Name: Ciprofloxacin Hcl

Brand Name: Requip XL
Generic Name: Ropinirole Extended Release Tablets

Brand Name: Zanaflex
Generic Name: Tizanidine

Brand Name: Noroxin
Generic Name: Norfloxacin

Brand Name: Maxaquin
Generic Name: Lomefloxacin Hcl

Brand Name: Ciloxan Ophthalmic Solution
Generic Name: Ciprofloxacin HCL Ophthalmic Solution

Brand Name: Cipro XR
Generic Name: Ciprofloxacin Extended-Release

Generic Name Norloaxin Brand Name: Noroxin

Generic Name Temafloxacin Brand name Omniflox